This early sequential phosphorylation of insoluble Tau is reflective of human dementia patients carrying the P301L Tau mutation and early asymptomatic stages of human AD around Braak stage I-III where Tau phosphorylation is the dominant Tau modification (Fig. 6) (Table S2). This evidence concerns the gene MAPT and Alzheimer disease.